TY  - THES
AB  - Monoclonal antibodies targeting key receptors that inhibit T cell function such as CTLA-4 and PD-1 have demonstrated the potency of checkpoint blockade, highlighted by long-term complete responses for metastatic cancers once thought incurable. However, only a subset of patients will respond to checkpoint blockade due to a multitude of factors including an immunosuppressive tumor microenvironment and the mutational burden of the cancer.
AU  - Emerson, Dana
DA  - 2021
DO  - 10.6083/37720d444
DO  - DOI
ID  - 9285
KW  - Neoplasms
KW  - CD8-Positive T-Lymphocytes
KW  - Immunotherapy
KW  - ibrutinib
L1  - https://digitalcollections.ohsu.edu/record/9285/files/Emerson.Dana.2021.pdf
L2  - https://digitalcollections.ohsu.edu/record/9285/files/Emerson.Dana.2021.pdf
L4  - https://digitalcollections.ohsu.edu/record/9285/files/Emerson.Dana.2021.pdf
LK  - https://digitalcollections.ohsu.edu/record/9285/files/Emerson.Dana.2021.pdf
N2  - Monoclonal antibodies targeting key receptors that inhibit T cell function such as CTLA-4 and PD-1 have demonstrated the potency of checkpoint blockade, highlighted by long-term complete responses for metastatic cancers once thought incurable. However, only a subset of patients will respond to checkpoint blockade due to a multitude of factors including an immunosuppressive tumor microenvironment and the mutational burden of the cancer.
PB  - Oregon Health and Science University
PY  - 2021
T1  - The role, function, and generation of Eomeshi CD8+ T Cells in OX40 and CTLA-4 targeted cancer immunotherapy
TI  - The role, function, and generation of Eomeshi CD8+ T Cells in OX40 and CTLA-4 targeted cancer immunotherapy
UR  - https://digitalcollections.ohsu.edu/record/9285/files/Emerson.Dana.2021.pdf
Y1  - 2021
ER  -